ArticleCritical care (London, England)2026
Longitudinal trajectories of functional outcome following aneurysmal subarachnoid hemorrhage: a retrospective study.
Article in Critical care (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Non-contrast computed tomography at the end of the acute care phase as an additional prognostic tool after aneurysmal subarachnoid hemorrhage.Neurosurgical review · 2026Article
- Access to care, treatment pathways, and outcomes of endovascular treatment for aneurysmal subarachnoid hemorrhage in Kazakhstan: a retrospective cohort study.Frontiers in radiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAneurysmal subarachnoid hemorrhage (aSAH) is associated with high mortality and disability. However, post-discharge functional trajectories within the first year after the bleed remain poorly characterized. Understanding recovery patterns is essential for guiding clinical decisions, counseling families, and optimizing rehabilitation strategies.
methodsWe retrospectively analyzed consecutive adults with imaging-confirmed aSAH admitted to the neurocritical care unit (NCCU) of the University Hospital Zurich between January 2016 and June 2024. Patients who survived hospitalization and had standardized follow-up assessments at 3 and 12 months were included. Functional outcome was evaluated using the Glasgow Outcome Scale-Extended (GOSE). Improvement was defined as an increase in GOSE between 3 and 12 months. Predictors of functional improvement were identified using multivariable logistic regression and ordinal shift analysis.
resultsAmong 342 hospital survivors, 301 were eligible for trajectory analysis. Overall, 58.5% of the 301 eligible survivors improved on the GOSE between 3 and 12 months, while functional decline was infrequent (≈ 6%). Excluding patients at the extremes of the scale (GOSE3 = 1 or 8, who by definition could not improve on GOSE), improvement rates ranged from 38% to 71% and were the highest in patients with moderate disability (GOSE at three months = 4). A higher Charlson Comorbidity Index (CCI) showed a consistent association with a lower likelihood of functional improvement: this effect did not reach the multiplicity-adjusted significance threshold in the primary multivariable logistic regression model but was directionally similar and nominally significant in the ordinal shift sensitivity analysis.
conclusionsPost-discharge recovery after aSAH is heterogeneous but often continues beyond three months. Pre-existing medical conditions seem to play an important role in outcome trajectories. Patients with moderate disability demonstrate the greatest potential for improvement, highlighting the importance of individualized rehabilitation and extended follow-up strategies after aSAH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.